CCR5 and early-onset autosomal dominant Alzheimer disease: Interestingly, RAGE has been described as a target for Alzheimer’s disease improvement and the prevention of amyloid deposition in the CNS [97,98,99,100,101,102], while increasing CCR5 expression and promoting leukocyte transmigration across the blood brain barrier [103].